Clene Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Rob Etherington

Chief Executive Officer (CEO)

US$2.2m

Compensación total

Porcentaje del salario del CEO	25.7%
Permanencia del CEO	11yrs
Participación del CEO	0.07%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rob Etherington en comparación con los beneficios de Clene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$50m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$2m	US$561k	-US$30m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	US$15m
Mar 31 2022	n/a	n/a	US$17m
Dec 31 2021	US$5m	US$510k	-US$10m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$55m
Dec 31 2020	US$498k	US$335k	-US$19m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$510k	US$335k	-US$16m
Dec 31 2018	US$465k	US$335k	-US$12m

Compensación vs. Mercado: Rob($USD2.18M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de Rob ha sido consistente con los resultados de la empresa en el último año.

CEO

Rob Etherington (56 yo)

11yrs

Permanencia

US$2,181,629

Compensación

Mr. Robert Etherington, also known as Rob, MBA, serves as Chief Executive officer, President and Director at Clene Nanomedicine, Inc. He serves as President, Chief Executive Officer and Director at Clene...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Etherington	CEO, President & Director	11yrs	US$2.18m	0.073% $ 31.1k
Morgan Brown	Chief Financial Officer	2.2yrs	US$1.19m	0% $ 0
Mark Mortenson	Chief Science Officer	no data	US$1.29m	0.13% $ 55.7k
Jerry Miraglia	General Counsel & Corporate Secretary	no data	sin datos	sin datos
Michael Hotchkin	Chief Development Officer	no data	sin datos	sin datos
Mary Mcneil	Head of Human Resources	no data	sin datos	sin datos
Benjamin Greenberg	Head of Medical	1.1yrs	sin datos	sin datos

2.2yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: CLNNEl equipo directivo de la empresa se considera experimentado (2 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Etherington	CEO, President & Director	11yrs	US$2.18m	0.073% $ 31.1k
David Matlin	Independent Chairman of the Board	3.3yrs	US$139.93k	5.6% $ 2.4m
Reed Wilcox	Independent Director	11.1yrs	sin datos	0.45% $ 189.7k
Jonathon Gay	Independent Director	3.3yrs	US$96.13k	0.14% $ 57.5k
Alison Mosca	Independent Director	4.6yrs	US$123.39k	3.69% $ 1.6m
Arjun Desai	Independent Director	less than a year	sin datos	0.013% $ 5.4k
Shalom Jacobovitz	Independent Director	11.1yrs	US$121.93k	0.058% $ 24.8k
Matthew Kiernan	Independent Director	less than a year	sin datos	0.0066% $ 2.8k
Vallerie McLaughlin	Independent Director	2.7yrs	US$106.84k	0% $ 0

3.3yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CLNN se considera experimentada (3 años de antigüedad promedio).

Clene Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Clene Inc., Annual General Meeting, May 29, 2024

Independent Chairman of the Board recently bought US$103k worth of stock

High number of new directors

Clene Inc. Announces Executive Changes

Independent Director recently bought US$253k worth of stock

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Recent updates

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension (LTE) Study Results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver

Clene Inc., Annual General Meeting, May 29, 2024

Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs

Clene Receives Notice from Nasdaq the Company Has Not Regained Compliance with the Minimum Bid Price Requirement

Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial

Price target decreased by 11% to US$5.00

Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases

Independent Chairman of the Board recently bought US$103k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Revenue and earnings growth

High number of new directors

Clene Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%, EPS downgraded

Price target decreased by 13% to US$5.83

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

New minor risk - Share price stability

Independent Director recently bought US$253k worth of stock

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Price target decreased by 20% to US$6.71

Consensus revenue estimates increase by 21%

New major risk - Shareholder dilution

Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (Nfl) Levels in the Healey Als Platform Trial

Clene Inc. has completed a Follow-on Equity Offering.

Clene Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 27%

Consensus revenue estimates decrease by 53%, EPS upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 10% to US$8.57

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$9.57

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Clene Inc. Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8(R) Treatment Improved Brain Neuronal Structural Integrity

Clene Inc. Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Clene Inc. and Clene Nanomedicine Inc, Announce the Visionary-MS Trial Results Were Featured as A Platform Presentation by Professor Michael Barnett At the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board recently bought US$2.9m worth of stock

High number of new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$10.57

Clene Inc. and Clene Nanomedicine Inc. Reports Topline Results Demonstrating Survival Signal for Cnm-Au8 in Healey Als Platform Trial

Investor sentiment deteriorated over the past week

Clene slips 13% as lead asset fails in ALS study

Clene Inc. and its Wholly Owned Subsidiary Clene Nanomedicine Inc. Present Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Consensus estimates of losses per share improve by 12%

Independent Director recently bought US$183k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

Investor sentiment deteriorated over the past week

Consensus forecasts updated

CEO, President & Director notifies of intention to sell stock

Clene ALS therapy gets EMA panel backing for orphan drug status

Clene Inc Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

Investor sentiment improved over the past week

Clene Inc.(NasdaqCM:CLNN) dropped from Russell 2500 Value Index

Investor sentiment improved over the past week

Co-Founder & Chief Science Officer notifies of intention to sell stock

Independent Chairman of the Board recently bought US$155k worth of stock

Investor sentiment improved over the past week

Clene Inc. Announces the Presentation of New Data from the its Phase 2 RESCUE-ALS Study at the European Network to Cure ALS (ENCALS) Meeting 2022

Independent Chairman of the Board recently bought US$79k worth of stock

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven